The battle against fatty liver disease, a global health concern affecting one in three adults, has taken an exciting turn. Researchers at the University of Barcelona have discovered a potential game-changer: two common drugs, pemafibrate and telmisartan, may be the key to reversing this condition. This breakthrough finding offers a glimmer of hope for those suffering from metabolic dysfunction-associated steatotic liver disease (MASLD), a condition that often leads to serious liver damage and increased cardiovascular risks.
A New Approach to an Old Problem
The challenge with treating MASLD has been the limited treatment options and the high failure rate of experimental drugs in clinical trials. Safety concerns often hinder progress, pushing scientists towards a more promising strategy: drug repurposing. By utilizing medications already approved for other conditions, this approach can be faster, more cost-effective, and safer, especially for the early stages of MASLD, which often go unnoticed.
Marta Alegret, the lead researcher, emphasizes the importance of this strategy, stating, "We have focused on these phases with the aim of preventing the disease from progressing to more severe stages. But for a drug to be used in these early stages, it must have a good safety profile in humans." This is where pemafibrate and telmisartan come into play.
The Power of Combination Therapy
The study, conducted on both rats and zebrafish larvae, revealed that the combination of pemafibrate and telmisartan was remarkably effective in reversing liver fat buildup caused by a high-fat, high-fructose diet. Interestingly, using half doses of both drugs together proved just as effective as using full doses of either drug alone, suggesting a synergistic effect.
Alegret explains, "Combination therapy with drugs acting on different pathogenic pathways may be a better strategy than monotherapy, thanks to possible synergistic effects and reduced toxicity related to the use of lower doses of each drug." This approach not only improves liver health but may also lower blood pressure and cholesterol levels, further reducing cardiovascular risks.
Unlocking the Mechanism
The study also uncovered the unique mechanisms behind the drugs' effectiveness. Researchers identified the PCK1 protein as a key player in telmisartan's ability to reduce liver fat. In animals with MASLD, PCK1 levels were lower than normal, and treatment with telmisartan restored these levels, altering the liver's nutrient processing.
Alegret notes, "This increase in PCK1 diverts the flux of metabolites from lipid synthesis to glucose synthesis. This increase in glucose production could be negative if the glucose were exported and accumulated in the blood, as it could lead to diabetes, but we have noticed that this is not the case."
A Promise Yet to Be Fulfilled
While the findings are exciting, it's important to remember that this research is still in its early stages. The study was conducted on animals, and more work is needed before the treatment can be tested in humans.
Alegret concludes, "In order to be translated into a treatment for MASLD patients, clinical studies would be needed to show that the benefits observed in animal models also occur in humans."
The team is now exploring the potential of the drug combination in more advanced stages of the disease, particularly when liver fibrosis is present. They are also developing new models that include both liver disease and cardiovascular conditions to assess the full scope of benefits.
In the words of Alegret, "We will develop a dual model involving liver fibrosis and cardiovascular disease to see if the beneficial action is observed not only in the liver, but also in the reduction of atherosclerosis."
This research marks a significant step forward in the fight against fatty liver disease, offering a promising new approach to a condition that has long been challenging to treat.
